Virus | Clade | 3E6B | 3E7B | scFv (HepB) | 1418 |
---|
92RW
|
A
|
45
|
>100
|
>150
|
>150
|
SF162
|
B
|
115
|
>100
|
>150
|
>150
|
QZ4589
|
B
|
50
|
>100
|
>150
|
>150
|
AIIMS 261
|
C
|
110
|
45
|
>150
|
>150
|
Du 422
|
C
|
>150
|
>100
|
>150
|
>150
|
ZM 53
|
C
|
>150
|
>100
|
>150
|
>150
|
- The cross neutralizing activities of two anti-V3 scFv clones against a panel of subtype-A, B, C viruses that are listed on the left. The numerical values in the table represent the concentration (μg/ml) of scFvs at which 50% neutralization titers (IC50) was reached. AIIMS 261 is the primary isolate generated in our lab from a HIV-1 clade C infected patient. scFv (HepB) is an scFv against the Hepatitis B surface antigen (negative control) and 1418 is human antibody to parvovirus (negative control). Each experiment was performed at least two independent times.